Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | FLT3 inhibitors: revolutionizing the management of AML

Naval Daver • 6 Sep 2024
SOHO 2024
Acute Myeloid Leukemia Leukemia Gilteritinib Midostaurin Quizartinib Venetoclax
ADMIRAL MORPHO QuANTUM-First RATIFY

Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role of FLT3 inhibitors in the treatment of acute myeloid leukemia (AML). He highlights several clinical trials that have pioneered the approval of various FLT3 inhibitors in both the frontline and relapsed/refractory (R/R) setting. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Naval Daver

Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perl et al. • 20 Sep 2026
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT3-mutated AML
3:31
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT3-mutated AML
Naval Daver • 8 Dec 2025
Pivekimab sunirine w/ venetoclax + azacitidine in unfit patients with newly diagnosed AML
2:25
Pivekimab sunirine w/ venetoclax + azacitidine in unfit patients with newly diagnosed AML
Naval Daver • 8 Dec 2025
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
2:30
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
Naval Daver • 8 Dec 2025

Related Videos

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
Managing FLT3-ITD mutant AML in remission
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
The content of VJHemOnc is intended for healthcare professionals